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Abstract
In the literature there are very few well-documented cases of myocardial ischemia with
pathomechanism accompanying allergic reaction. It is defined as Kounis syndrome, i.e. an-
gina pectoris or infarction with allergic etiology. It is suggested, that few few cases of myocar-
dial ischemia after a Hymenoptera sting reported thus far represent only a minute percentage
of the total number of allergic reactions which occur in the circulatory system. It is difficult to
make a credible decision whether allergic mechanisms are responsible for a greater number of
deaths than we suspect.
In the light of the literature, this review deals with current views regarding pathomechanisms
of myocardial ischemia in the course of anaphylactic reaction and presents the clinical mani-
festation of myocardial ischemia with an allergic background, pointing out that allergic reac-
tions involving cardiac muscle are not limited to the development of ischemia. The term organ
anaphylaxis, in relation to the heart, also comprises rhythm and contractility disturbances
which are present after exposure to the allergen.
At the same time, the authors touch upon therapeutic aspects of immunotherapy in patients
with significant cardiovascular risk and draw attention to the possibility of an alternative
treatment for patients with allergic history, not only during desensitization but also for long-
-term outpatient treatment. (Cardiol J 2008; 15: 220–225)
Key words: allergic myocardial infarction, anaphylactic shock, immunotherapy
Introduction
Symptoms of myocardial ischemia accompany-
ing allergic reactions are defined in the literature
as Kounis syndrome or allergic angina/myocardial
infarction [1]. In 1998 Braunwald [2] noted that va-
sospastic angina can be induced by “allergic reactions
with mediators such as histamine or leukotrienes
acting on coronary vascular smooth muscle”. It has
been nearly 15 years since the announcement made
by Kounis about the contraction of coronary arte-
ries which was induced by histamine in the course
of allergic reaction, but in the literature one can find
very few well-documented cases of myocardial
ischemia of such pathogenesis [3, 4].
Allergic reactions following a Hymenoptera
sting have three main clinical manifestations: exces-
sive local reaction, systemic reaction and delayed
type of reaction. These types of reactions can oc-
cur even following minimal doses of venom. After
stinging by a higher number of insects (from tens
to hundreds of stings), one can observe toxic symp-
toms resulting from the direct cytotoxic effect of
venom components (i.e., melittin, apamine) [5].
The anaphylactic reaction can develop after
a sting to any part of the body, but the most predi-
sposed areas are the head, neck and throat. If car-
diac ischemia develops, an angina type chest pain
occurs within several tens of minutes after stinging [6].
Myocardial ischemia, in the course of anaphylactic
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reaction, can result from circulatory system insta-
bility (drop in coronary perfusion pressure) and
pathophysiologically it does not differ from distur-
bances which are seen in shock, regardless of its
etiology [3, 7]. However, allergic reactions can lead
to myocardial ischemia as a result of coronary ves-
sel contraction. This form of ischemia is defined as
allergic angina (Kounis syndrome). Its most com-
mon symptoms, beside typical stenocardial pain, are
the following: dyspnoe, palpitation, serious weak-
ness, nausea, vomiting, fainting, urticaria, itching,
profuse sweating, paleness, hypotonia and someti-
mes bradycardia.
Acute coronary syndromes
with allergic etiology
Two types of Kounis syndrome are recognized:
type I occurs in patients with angiographically nor-
mal coronary vessels, whereas in type II concomi-
tant atheromatic lesions are found. Vasospasm de-
velops in both types. However, in type I, the only
cause responsible for ischemia and the probable
mechanism leading to vasospasm is the dysfunction
of endothelium [8].
Under such conditions, substances released
during allergic reaction, among them histamine,
lead to vasospasm, whereas in normal vessels va-
sodilatation occurs [9].
Usually, at least 30 min elapse from the expo-
sure to the allergen to the development of anginal
pain [3, 8], while the half-life of the histamine in
circulation is estimated at about eight minutes.
Therefore, it seems that the pathomechanism of
myocardial infarction is more complicated and can-
not be considered exclusively as a vasospasm evo-
ked by histamine [8]. In type II Kounis syndrome,
the constriction of vascular walls leads to the rup-
ture of atheromatic plaque, mostly at its margin.
Additional factors predisposing atheromatic plaque
to rupture are proteolytic enzymes such as chyma-
se and tryptase, which, when released by activated
mast cells, degrade the collagen cover of the lipid
core of the plaque. As a result of the plaque lesion,
thrombogenic material is exposed and the process
of coagulation starts. The coronary vessel is then
closed in a mechanism typical for classic acute co-
ronary syndrome. Moreover, exposure to allergen
enhances platelet aggregation with the help of se-
rotonin, adrenalin, bradykinin, leukotrienes and
thromboxane [4].
Considering the scarcity of descriptions of
myocardial infarction with proven allergic etiology,
credible data regarding the relative frequency of
both types of syndrome is hard to obtain. In the
period of two years, one intensive cardiac care cen-
tre treated eight patients with acute coronary syn-
drome who had been stung by Hymenoptera insects
in the preceding 48 hours. In all patients who un-
derwent coronarography, the presence of at least
one narrowing > 70% in coronary vessels (type II
Kounis syndrome) was found [10]. On the basis of
the aforesaid data, one can assume that type II of
the syndrome occurs more often. The authors sug-
gest that atopic patients, having higher proneness
to degranulation of mast cells, are more exposed to
the destabilization of atheromatic plaque in the co-
urse of allergic reaction, compared with non-atopic
patients [10].
Mechanisms of allergic coronary syndromes
Acute coronary events in the course of aller-
gic reaction were described after exposure to
Hymenoptera venom [11], food allergens (e.g. shell-
fish) [8, 12],  intravenous [11] and even oral drugs [13].
Acute vascular neurological events were also repor-
ted after insect stings [14]. It could be hypothesi-
zed that similar changes (vessel contraction and/or
lesion of pre-existing atheromatic plaque) can also
take place in cerebral circulation. There are a lot of
factors and diseases which may evoke Kounis
syndrome (Table 1).
Few cases of myocardial ischemia have been
proven to have an etiological connection with
Hymenoptera stings. They are probably only a small
proportion of the allergic reactions occurring in real
Table 1. Kounis syndrome — possible etiologic
factors [8, 13, 15, 16].
Diseases Drugs Venoms
and toxins
Angioneurotic Antibiotics Viper venom
oedema Bupropion Wasp venom
Bronchial asthma Contrast media Bee venom
Exercise induced Glucocorticoids
anaphylaxis Dextran
Food allergy Heparin
Idiopathic  Intravenous
anaphylaxis anesthetics
Serum sickness NSAID
Urticaria Protamine
Skin disinfectants
Streptokinase
NSAID — non-steroids anti-inflammatory drugs
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life in the cardiovascular system. It is possible that
coronary vasospasm during coronarography may
have an allergic origin as well. In this case it would
be a form of organ restricted allergy. Moreover,
sudden deaths caused by allergic mechanisms are
probably underestimated as well. In statistical data
from England, on average only four deaths a year
are caused by Hymenoptera stings. However, it is
suggested that the majority of acute deaths caused
by stings remain undiagnosed [17]. Steady growth
in the prevalence of atopic diseases would suggest
an increase in the number of cardiologic cases of
allergic etiology is to be expected.
The key elements of organ allergic reaction are
mast cells located in the heart. They are present
between cardiomyocytes, in the internal layer of
arteries and around coronary vessels [18–20].  They
are found in the hearts of healthy humans, but at
the same time occur in considerably higher amo-
unts in the intima and adventitia of vessels with pre-
existing atheromatic lesions, particularly in margi-
nal regions of atherosclerotic plaques. Cardiac mast
cells possess specific immunohistochemical featu-
res distinguishing them from mast cells of other
organs. Probably the activation of mast cells accu-
mulated around atheromatic foci is one of the key
steps leading to their destabilization. In place of
plaque rupture, about 200 times more mast cells are
found compared with surrounding vascular seg-
ments without atheromatic changes, in patients with
non-allergic acute myocardial infarction [8, 19, 21].
The majority of mast cells in coronary vessels,
especially in marginal regions of atheromatic pla-
ques, contain both tryptase and chymase [22]. Mast
cells can be activated by T lymphocytes and macro-
phages [23]. The classic example of mast cell sti-
mulation is its activation trough immunoglobulin
IgE (IgE). During IgE dependent mast cell degra-
nulation, a specific antigen reacts with one or more
IgE particles bounded with mast cells through the
high affinity receptor FceRI.
In the course of anaphylactic reaction, a com-
plement is activated with the anaphylotoxin gene-
ration. The specific receptors for them are present
on the surface of cardiac mast cells [24]. The final
step of this processes is mast cell degranulation,
resulting in histamine, tryptase and chymase rele-
ase, as well as in prostaglandin and leukotriene syn-
thesis. The histamine concentration is elevated in
arterial walls containing atheromatic changes [25].
Similarly, the number of mast cells in vascular ad-
ventitia increases proportionally with the extent of
atherosclerosis. A higher number of mast cells is
found in coronary vessels containing acute athero-
thrombotic changes, whereas in already organized
thrombi the number is low [26]. Peptidases rele-
ased form stimulated mast cells activate metallo-
proteinases (MMP: MMP-1, MMP-3 and MMP-9)
which degrade connective tissue covering the athe-
romatic plaque. The plaque becomes vulnerable i.e.
more prone to rupture. If the fibrous cap covering
the lipid core splits, acute coronary syndrome evo-
lves. Moreover, prostaglandin D2, leukotrienes and
angiotensin II formed under chymase influence con-
tract coronary vessels [27]. They may trigger vul-
nerable plaque rupture and facilitate vessel closu-
re. The next factor playing an important role in athe-
rothrombosis is the tumour necrosis factor a
(TNF-a), a strong pro-inflammatory cytokine,
which, if released from mast cells, activates inflam-
mation and transforms stable plaque into vulnera-
ble plaque [28].
It was shown that activated mast cells were
present around the rupture in the atherosclerotic
plaque. If it is possible to prove the role of mast cells
in plaque destabilization even in acute coronary
syndromes not of allergic origin, a common final
pathway could be discovered. The well-known mecha-
nisms leading to plaque destabilization — oxidized
LDL or allergic processes — also stimulate inflam-
mation [19, 21, 29–32]. Rupture of the atheromatic
plaque and thrombus formation with subsequent ves-
sel closure would be the final step of any mechanism
stimulating inflammation and therefore destabilizing
plaque, regardless of the initiating factors.
If this hypothesis were proven, knowledge abo-
ut the common final pathway leading to plaque de-
stabilization could widen the range of available the-
rapeutic methods in the prophylaxis of acute coro-
nary syndromes. In light of this, drugs which inhibit
the degranulation of mast cells could become the
successive tool for atheromatic plaque stabilisation.
Initial experiments investigating the prevention of
acute coronary syndromes with drugs originally
used in patients with asthma have already started.
If mast cell activation proves to be a universal phe-
nomenon leading to plaque destabilization, the
efficiency of drugs which stabilize mast cell mem-
branes in the prevention of acute coronary syndro-
mes can be expected [15].
Type I Kounis syndrome
and Prinzmetal angina
Many similarities between type I Kounis syn-
drome and Prinzmetal angina have been observed.
In both cases, the key element resulting in myocar-
dial ischemia is the contraction of vessels. It often
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develops in places angiographically unchanged.
However, intravascular ultrasonography reveals, at
least in some cases, the presence of minimal athe-
romatic lesions in such places [33]. Stimuli which
cause vasospasm in Prinzmetal angina are similar
to factors released during allergic reactions; among
others: catecholamines, thromboxane A2, serotonin,
endothelin, vasopressin [34] and histamine [35].
In blood taken from the coronary sinus of variant
angina patients, elevated concentrations of histami-
ne were seen [15, 19, 35]. Cuculo and co. observed
transient serum tryptase concentrations several
times higher in patients with unstable angina after
chest pain episodes. This suggests that mast cells
are activated during unstable angina, but the stimu-
lus remains unrecognized [27].
Substances indicating mast cell activation are
present in the circulation in both allergic and non-
allergic episodes of acute myocardial ischemia [8].
It was also shown that some patients with Prinzme-
tal angina, with normal coronary angiography, evo-
lve typical chest pain with accompanying ST eleva-
tion after intravenous histamine administration
(dose ranges 0.5–1 mcg/kg b.w./min) [36]. This
observation is important not only in the diagnostic
aspect of variant angina, but, probably more impor-
tantly, it proves that the administration of histami-
ne releasing drugs (e.g. opiates and some relaxants)
can cause coronary vessels spasm in susceptible
patients [36]. In vitro studies have revealed that
human coronary arteries afflicted with atheroscle-
rosis were more susceptible to vasoconstriction
caused by catecholamines, 5-hydroxytryptamine
and histamine, compared to vessels without athe-
romatic lesions. The biggest difference was obse-
rved for histamine, which contracts atherosclero-
tic vessels about 1000-times stronger than the un-
changed ones. Moreover, coronary segments with
atheromatic lesions contain nearly two times more
histamine than adjacent unchanged segments.
Similar differences in histamine content were found
by postmortem study between coronary arteries
taken from patients with ischemic heart disease and
from people who died due to other reasons. No such
differences were found for 5-hyroxytryptamine and
catecholamines. In people with coronary artery
disease, mast cells are present in adventitia in amo-
unts proportional to the intensity of atherosclero-
tic changes. Increased content of histamine and
mast cells in walls of diseased coronaries proves
that the mediator can be released in high amounts
in response to various stimuli. This might result in
strong coronary artery contraction leading to flow
decrease, chest pain and rhythm disturbances [37].
In literature attempts were described to coun-
teract the actions of inflammatory mediators by
using, experimentally, mediator antagonists, inhi-
bitors of mediator biosynthesis and mediator recep-
tor blockers. Leung et al. [38], in a recent study,
applied anti-IgE therapy with humanized IgG1 mo-
noclonal antibodies to mask the region of mast cell
surface responsible for IgE binding thus offering
protection against mast cell degranulation. It has
also been suggested that in atopic patients treat-
ment with anti-IL-4Ra antibodies might inhibit acu-
te allergic episodes [39]. All these agents capable
of stabilizing and protecting mast cell membrane
could also prevent acute thrombotic events [7].
Clinical manifestation of myocardial
ischemia with allergic etiology
Allergic reactions relating to cardiac muscle are
by no means limited to the development of ischemia.
The term organ anaphylaxis, regarding the heart,
also includes disturbances of rhythm and contrac-
tility which occur after exposure to allergens.
In the beginning, it was reckoned that lesions
relating to the heart are only the result of systemic
disturbances, such as drop in arterial pressure,
growth of resistance in airways and disturbances of
ventilation. However, changes resembling those
symptoms developing in the heart in vivo were also
observed in isolated organs (in vitro) of guinea pigs,
in response to allergens after previous passive al-
lergisation [40, 41]. In in vitro experiments, anti-
gen administration into coronary circulation triggers
histamine release. Similar changes occur after pa-
renteral application of antigen in vivo. Exposure to
the allergen evokes a transient, profound drop in
contractility and rhythm disturbances as sinus ta-
chycardia, atrio-ventricular blocks, ventricular ta-
chycardia or idioventricular rhythm. Intensity of the
described reaction is in proportion to the amount
of released histamine, but this relationship is not
linear. This proves the co-participation of other
mediators in the development of disturbances [41].
In the ECG in the course of anaphylactic reaction,
as well as rhythm disturbances, one can observe
flattening or inversion of T waves and ST segment
displacement (depression or elevation) [42]. The
ectopic and sinoatrial node automatism stimulation
is H2 receptor dependent, whereas conductance
disturbances are H1 receptor mediated [41].
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Therapeutic problems related
to immunotherapy
Specific immunotherapy of patients with seve-
re life-threatening allergic reactions in anamnesis
is associated with a risk of adverse events. The risk
is particularly high during the administration of hi-
gher concentrations of allergen and in cases of de-
sensitization with venom of Hymenoptera insects.
The risk of systemic reactions during the immuno-
therapy is estimated at about 10% [17]. Despite the
fear of adverse events related to the specific immu-
notherapy in such patients, the prevailing opinion
is that desensitization is the only form of treatment
that significantly decreases the risk of life-threate-
ning allergic reaction in the case of another sting [6].
There is no data from controlled trials concerning
the role of specific immunotherapy in allergic myo-
cardial infarction survivors. Repeated uncontrolled
allergen exposition after past infarction is probably
associated with the threat of another infarction.
However, do we know enough to qualify the patient
after allergic myocardial infarction to specific im-
munotherapy? Sometimes the significant left ven-
tricle systolic dysfunction results from acute coro-
nary events. Advanced heart failure is a commonly
accepted contraindication to immunotherapy. For
patients with compromised left ventricular function,
after an allergic event, another episode may be fa-
tal. It is estimated that the risk of serious systemic
reaction in the case of another sting is 50%. Having
taken into account the relative contraindications,
the authors attempted to administer specific immu-
notherapy to the patient with post-myocardial ven-
tricular systolic dysfunction, without any undesira-
ble circulatory side effects [43]. Violent local reac-
tions do not announce systemic reactions and
therefore are not an indication for desensitization.
According to current recommendations, the
prevalence of local reactions during immunothera-
py, found in up to 25% of desensitized patients, does
not increase the risk of treatment-related serious
systemic reactions and is not an indication for
a change in dosage regimen [37, 44]. In patients with
different forms of ischemic heart disease (especially
after myocardial infarction), the use of beta-blockers
and angiotensin converting enzyme inhibitors
(ACEI) is standard. Unfortunately, treatment with
these drugs is related to a higher risk of serious
anaphylactic reactions which are, moreover, diffi-
cult to treat [45–48]. Similar unfavourable effects
of these drugs can be expected after exposure to
an allergen (e.g. Hymenoptera sting) in real life.
As much as possible, it is worth considering
switching the patient to alternative treatment (for
example with angiotensin II receptor blockers in-
stead of ACEI) in patients with allergic history
during desensitization and probably in long-term
treatment on an outpatient basis [49].
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